Registered business · FR · Founded 2023 · Accounts through 2024 · Updated Jul 25, 2026
Public range today€500k - €1.1m
See what is holding the value back today, what this company could be worth in five years and which actions make the difference. The estimate is based on filed annual accounts.
Is this your company? Claim and manage this profile
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsThe historical valuation curve is public. Create a free account for the future five-year growth forecast, the insights behind it, and concrete action points that can increase this company’s value.
Free account · private workspace
Public filings are a starting point. Accounts, owner context and method review narrow the range and make it useful for a sale, financing or transfer.
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for BEMIPHARM combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
Register your interest privately. Upswitch reviews every request and keeps it queued until a safe, verified owner contact route is available.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Claim this companyBEMIPHARM, a business in NACE sector 74.90, is registered at an address in France. The company was founded in 2023.
BEMIPHARM is listed in French National Business Register (RNE/INPI) under registry number 949752307. This profile consolidates official annual accounts into one indexable company dossier.
Within the French NACE 74.90 cluster, public-record data is filed annually via the national company registry.
Across the 2023-2024 window revenue has more than doubled, moving from €96,950 to €2,540,873.
A public indicative value curve is available for BEMIPHARM, based on filed company accounts. A free account unlocks the five-year outlook and concrete actions to increase value.
The most recent annual filing covers 2024 (period end 2024-12-31).
The data on this page is a public, point-in-time projection of BEMIPHARM's regulator-filed footprint, built to support indicative valuation bands, sellability context, and acquisition research.
Public regulator-filed figures across 2 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202431 Dec 2024 | €2,540,873 | - | €4,683,958 | €223,492 | - |
| 202331 Dec 2023 | €96,950 | - | €146,238 | €91,556 | - |
BEMIPHARM was founded in 2023 and is registered with French National Business Register (RNE/INPI).
BEMIPHARM is registered under NACE 74.90. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-12-31), publicly available via French National Business Register (RNE/INPI).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for BEMIPHARM may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
